Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
18F-Flutemetamol (Vizamyl) is a radioactive diagnostic agent indicated and FDA-approved for
Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque
density in adult patients with cognitive impairment who are being evaluated for Alzheimer's
disease (AD) or other causes of cognitive decline. This study is designed to evaluate a novel
use for 18F-Flutemetamol in cardiac amyloidosis.